PHARMASCIENCE INC
GenericsPHARMASCIENCE INC is a generic drug manufacturer focused on Oncology.
PHARMASCIENCE INC at a Glance
- Strong track record with 100% execution quality across 5 trials
- Fast trial execution (2 months median completion)
PHARMASCIENCE INC's Key Drugs
PHARMASCIENCE INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PHARMASCIENCE INC's Recent FDA Approvals
PHARMASCIENCE INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
PHARMASCIENCE INC's Therapeutic Areas
PHARMASCIENCE INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARMASCIENCE INC's Top Competitors
PHARMASCIENCE INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARMASCIENCE INC Pipeline Snapshot
Active clinical trials for PHARMASCIENCE INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 2 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2017-03-24
- Latest
- 2024-02-15
- Applications
- 7
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges